Loading...
The monoclonal antibody bamlanivimab was recently granted an emergency use authorization to treat COVID-19 outpatients at risk for severe disease or hospitalization. In the latest HIV and ID Observations post, Dr. Paul Sax discusses the difficulty of actually giving this product to a stable, high-risk outpatient with COVID-19.